autologous hematopoietic stem cells genetically engineered to express a CD4 CAR and the C46 peptide (University Of California Los Angeles)

N/A

Report date: 2025/03/18 18:07:01

Base Information

Drug Nameautologous hematopoietic stem cells genetically engineered to express a CD4 CAR and the C46 peptide (University Of California Los Angeles)

Drug Alias NameC46CD4CAR-modified hematopoietic stem cells

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionHIV envelope protein gp120 modulators

TargetsHIV envelope protein gp120

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California, Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, Los Angeles

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A